Роль современных технологий послеоперационной лучевой терапии в комбинированном лечении немелкоклеточного рака легкого

1. Вальков М. Ю., Скрипач Ю. В., Соловьева Е. П. с соавт. Методы лечения и исходы при местно-распространенном раке легкого III стадии: популяционный анализ. // Вестник РНЦРР. – 2014. – № 9. – стр. 9.

2. Миллер С. В., Тузиков С. А., Завьялов А. А. с соавт. Анализ осложнений комбинированного лечения немелкоклеточного рака легкого. // Сибирский онкологический журнал. – 2007. – Т. 4. – С. 50–56.

3. Михина З. П., Горбунова В. А., Ткачев С. И. с соавт. Современная химиолучевая терапия больных с немелкоклеточным раком легкого. // Медицинская радиология и радиационная безопасность. – 2012. – Т. 57. – № 2. – С. 26–30.

4. Паршин В. Д., Белов Ю. В., Выжгина М. А. Хирургия злокачественных опухолей легкого у больных старше 70 лет. // Хирургия. Журнал им. Н. И. Пирогова. – 2010. – № 10. – С. 11–16.

5. Петерсон Б. Е. Рак легкого. // М. Медицина. – 1971. – С. 24–26.

6. Солодкий В. А., Харченко В. П., Чхиквадзе В. Д. и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. сообщение II. Безрецидивная выживаемость и выживаемость без локорегионарного рецидива. // Вопросы онкологии. – 2016. – Т. 62. – № 1. – С. 72–78.

7. Трахтенберг А. X., Колбанов К. И., Вурсол Д. А. Расширенные и комбинированные операции при местно-распространенном немелкоклеточном раке легкого. // Российский онкологический журнал. – 2007. – № 2. – С. 9–14.

8. Троценко С. Д., Солодкий В. А., Сотников В. М. и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. Общая и болезнь-специфичная выживаемость. // Вопросы онкологии. – 2015. – Т. 61. – № 1. – С. 71–76.

9. Харченко В. П., Волохов В. Э. Комбинированное лечение больных раком легкого. // Материалы научной работы по онкологии. – 1966. –С. 38–42.

10. Харченко В. П., Кузьмин И. В. Рак легкого. Руководство для врачей. // М.: Медицина. – 1994. – стр. 92.

11. Харченко В. П., Чхиквадзе В. Д., Паньшин Г. А. Комбинированое и хирургическое лечение больных раком легкого. // Вестник Московского Онкологического Общества. – 2009. – № 9. – стр. 5.

12. Яблонский П. К., Петров А. С. Видеомедиастиноскопия и другие методы N-стадирования в хирургии рака легкого // Геотар-Медиа. – 2015. – С. 26–28.

13. Arriagada R., Auperin A., Burdett S. et al: Adjuvant chemotherapy with or without postoperative radiotherapy in operable non-small-cell lung cancer: two meta-analyses of individual patient data. // Lancet. – 2010. – V. 375. – P. 1267–1277.

14. Astudillo J., Conill C. Role of postoperative radiation therapy in stage IIIa non-small cell lung cancer. // Ann Thorac Surg. – 1990. – V. 50. – P. 618–623.

15. Billiet C., Decaluwe H., Peeters S. et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. // Radiother. Oncol. – 2013. – V. 110. – № 1. – P. 3–8.

16. Billiet C., Gouw Z., Defraene G. et al. Postoperative radiotherapy in resected ypN2 stage III-N2 non-small cell lung cancer: can modern conformal radiotherapy compensate for the poor outcome? // Annals of Oncology. – 2014. – V25. – № 4. – P. 417–425.

17. Chung C. K., Stryker J. A., O”Neill M. Jr. et al. Evaluation of adjuvant postoperative radiotherapy for lung cancer. // Int J Radiat Oncol Biol Phys. – 1982. – Т. 8. – P. 1877–1880.

18. Corso C. D., Rutter C. E., Wilson L. D. et al. Re-evaluation of the Role of Cancer Using the National Cancer Database. // J. Thorac. Oncol. – 2015. – V. 10. – P. 148–155.

19. Douillard J. Y., Rosell R., De Lena M. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. // Lancet Oncol. – 2006. – V. 7. – P. 719–727.

20. Fan C, Gao S, Hui Z, Liang J, Lv J, Wang X et al (2013) Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy. // Radiat Oncol. – V. 8. – P. 286.

21. Goldstraw P., Crowley J., Chansky K. et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours // J. Thorac. Oncol. – 2007. – V. 2. – P. 706–714.

22. Ichinose Y., Kato H., Koike T. et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: Questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. // Lung Cancer. – 2001. – V. 34. – P. 29–36.

23. International Adjuvant Lung Cancer Trial Collaborative Group. Arriagada R., Bergman B., Dunant A. et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. // N Engl J Med. – 2004. – V. 350. – P. 351–360.

24. Jemal A., Bray F., Center M. M. et al. Global cancer statistics. CA Cancer J Clin. – 2011. –V. 61. –P. 69–90.

25. Kelsey C. R., Marks L. B., Hollis D. et al. Local recurrence after surgery for early stage lung cancer: An 11-year experience with 975 patients. // Cancer. – 2000. – V. 115. – P. 5218–5227.

26. Kepka L., Bujko K., Orlowski T. M. et al. Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy. // Radiother. Oncol. – 2011. – V. 98. – № 2. – P. 238–243.

27. Kirsh M. M., Sloan H. Mediastinal metastases in bronchogenic carcinoma: Influence of postoperative irradiation, cell type and ocation. // Ann Thorac. – 1982. – Т. 33. – P. 459–463.

28. Kolodziejczyk М., Bujko K., Michalski W., Kepka L. Incidence of isolated nodal failure in non-small cell lung cancer patients included in a prospective study of the value of PET – CT. // Radiotherapy and Oncology. – 2012. – V. 104. – № 1. – P. 58–61.

29. Lally B. E., Detterbeck F. C., Geiger A. M. et al. The risk of death from heart disease in patients with non-small cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. // Cancer. – 2007. – V. 110. – № 4. – P. 911–917.

30. Landreneau J. P., Schuchert M. J., Weyant R. et al. Anatomic segmentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer (NSCLC). // Surgery. – 2014. – V. 155. – P. 340–346.

31. Machtay M., Lee J. H., Shrager J. B., Kaiser L. R., Glatstein E. Risk of Death From Intercurrent Disease Is Not Excessively Increased by Modern Postoperative Radiotherapy for High-Risk Resected Non – Small-Cell Lung Carcinoma. // Journal of Clinical Oncology. – 2001. – V. 19. – № 19. – P. 3912–3917.

32. Patela S. H., Mab Y., Wernickea A. G. et al. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer. // Lung Cancer. – 2014. – V. 84. – P. 156–160.

33. Paterson R., Russell M. H. Clinical trials in malignant disease. Part-IV-Lung Cancer. Value of post-operative radiotherapy. // Clinical radiology. – 1962. – P. 141–144.

34. Pignon J. P., Tribodet H., Scagliotti G. V. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. // J Clin Oncol. – 2008. – V. 26. – P. 3552–3559.

35. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. // Lancet. – 1998. – V. 352. – P. 257–263.

36. Robinson C. G., Patel A. P., Bradley J. D. et al. Postoperative Radiotherapy for Pathologic N2 Non – Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base. // J. Clin. Oncol. – 2015. – V. 34. – P. 2–8.

37. Sawyer T. E., Bonner J. A., Gould P. M. et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. // Ann Thorac Surg. – 1997. – Т. 64. – P. 1402–1408.

38. Su S., Scott W. J., Allen M. S. et al. Patterns of survival and recurrence after surgical treatment of early stage non – small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. // J. Thorac Cardiovasc. Surg. – 2014. – V. 147. – P. 747–753.

39. Thames H. D. Postoperative radiotherapy of non-small cell lung cancer: a flow in the PORT meta-analysis. // Progress in Radiotherapy VII. – Bologna. – 2002. – P. 9–16.

40. Wakelee H. A., Stephenson P., Keller S. M. et al. Post-operative radiotherapy or chemoradiotherapy following resection of stages II and IIIA non-small cell lung cancer does not increase the expected risk of death from intercurrent disease in Eastern Cooperative Oncology Group trial E3590. // Lung Cancer. – 2005. – V. 48. – P. 389–397.

41. Wang Y., Li B., Huang W. et al. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with non-small-cell lung cancer: a study of 2062 cases. // Br. J. Radiol. – 2015. – V. 88. – P. 1–8

42. Warren M., Webster G., Ryder D. et al. An isotoxic planning comparison study for stage II-III non-small cell lung cancer: is intensity-modulated radiotherapy the answer? // Clinical Oncology. – 2014. – V. 26. – № 8. – P. 461–467.

43. Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. //

44. N. Engl. J. Med. – 2005. – V. 352. – № 25. – P. 2589–2597.

45. Zhang Y., Sun Y., Xiang J. et al. A prediction model for N2 disease in T1 non – small cell lung cancer. // J. Thorac Cardiovasc. Surg. – 2012. – V. 144. – P. 1360–1364.

46. Zhang Y., Sun Y., Xiang J. et al. A clinicopathologic prediction model for postoperative recurrence in stage Ia non – small cell lung cancer. // J. Thorac Cardiovasc. Surg. – 2014. – V. 195. – № 2. – P. 1–7.